Ken Griffin Myriad Genetics Inc Put Options Transaction History

Citadel Advisors LLC

  • $509 Billion
  • Q1 2024

Put Options

6 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q1 2024

May 15, 2024
SELL
$17.59 - $23.59 $165,346 - $221,746
-9,400 Reduced 39.66%
14,300 $304,000
Q4 2023

Feb 14, 2024
BUY
$13.91 - $21.32 $148,837 - $228,124
10,700 Added 82.31%
23,700 $453,000
Q3 2023

Nov 14, 2023
BUY
$15.99 - $23.22 $63,960 - $92,880
4,000 Added 44.44%
13,000 $208,000
Q2 2023

Aug 14, 2023
BUY
$17.56 - $23.76 $105,359 - $142,560
6,000 Added 200.0%
9,000 $208,000
Q1 2023

May 15, 2023
BUY
$15.26 - $23.75 $3,052 - $4,750
200 Added 7.14%
3,000 $69,000
Q4 2022

Feb 14, 2023
BUY
$14.51 - $20.99 $40,628 - $58,771
2,800 New
2,800 $40,000

Others Institutions Holding MYGN

# of Institutions
191
Shares Held
94.2M
Call Options Held
280K
Put Options Held
14.3K
View Full List

About MYRIAD GENETICS INC

MYGN Quotes by TradingView
  • Ticker MYGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 80,634,800
  • Market Cap $1.97B
  • Description
  • Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing ...
More about MYGN
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email